@article{TAU1160,
author = {Jorge Camarero and Sol Ruiz},
title = {Immunotherapy in renal cell cancer: the more the merrier?},
journal = {Translational Andrology and Urology},
volume = {2},
number = {2},
year = {2012},
keywords = {},
abstract = {Renal cell carcinoma (RCC) is the most common primary malignancy affecting the kidney and considered a disease refractory to systemic therapy beyond cytokine therapy (the use of interferon alfa and interleukin 2 was limited when targeted therapies became available) (1). Currently, eight drugs are approved in the European Union (EU) for the treatment of advanced RCC, including IL-2, IFN-α, sorafenib, sunitinib, everolimus, temsirolimus, bevacizumab in combination with IFN-α, and pazopanib.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/1160}
}